FDA staff sug­gests safe­ty pro­file of Sage post­par­tum de­pres­sion drug dis­qual­i­fies it from at-home in­fu­sions

Ahead of Fri­day’s ad­vi­so­ry com­mit­tee pan­el on Sage Ther­a­peu­tics’ $SAGE brex­anolone, FDA re­view­ers rec­om­mend­ed that the post­par­tum de­pres­sion drug be ad­min­is­tered in the pres­ence of …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER